ReviewFrontiers in pharmacology2025
Advances in pulmonary neuroendocrine cells and their cellular interactions in asthma pathogenesis.
Review in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The Role of the Nervous System in Lung Disease.Current neurology and neuroscience reports · 2026Review
- Pulmonary neuroendocrine cells in pediatric asthma and bronchopulmonary dysplasia: neuroimmune-developmental mechanisms and translational implications.Frontiers in medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Asthma is a complex chronic inflammatory airway disease, whose pathogenesis involves interactions among multiple cell types and molecular pathways. Pulmonary neuroendocrine cells (PNECs), rare epithelial cells in the lungs, have recently gained attention as pulmonary sensors. PNECs detect environmental signals and regulate pulmonary immune responses and physiological functions by releasing neuropeptides and neurotransmitters. Aberrant activation of PNECs is implicated in various respiratory diseases, including asthma, where they interact significantly with other cell types, such as type 2 innate lymphoid cells (ILC2s), goblet cells, and eosinophils. Recent studies have highlighted the potential of targeting PNEC-related pathways for developing novel anti-inflammatory drugs and identifying biomarkers to evaluate drug efficacy and toxicity in asthma. Exploring asthma pathogenesis through the functional characteristics of PNECs and their interactions with other cells could have potential clinical value in diagnosing and treating of asthma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.